MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.60
+0.25
+1.60%
After Hours: 15.60 0 0.00% 16:09 11/15 EST
OPEN
15.42
PREV CLOSE
15.36
HIGH
15.78
LOW
15.26
VOLUME
834.86K
TURNOVER
--
52 WEEK HIGH
15.78
52 WEEK LOW
3.920
MARKET CAP
979.52M
P/E (TTM)
-4.5570
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KPTI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KPTI News

  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.2d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.3d ago
  • Edited Transcript of KPTI earnings conference call or presentation 4-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
  • GlobeNewswire.11/06 15:12

More

Industry

Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About KPTI

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More

Webull offers Karyopharm Therapeutics Inc (KPTI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.